Overview

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-01-04

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.

Phase:

PHASE2

Details

Lead Sponsor:

Amgen

Treatments:

inebilizumab